[CAS NO. 745833-23-2] VX-702
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [745833-23-2]
Store
Catalog
SLK-S6005
Brand
Selleck
CAS
745833-23-2
DESCRIPTION [745833-23-2]
Overview
| MDL | MFCD11616590 |
|---|---|
| Molecular Weight | 404.3 |
| Molecular Formula | C19H12F4N4O2 |
| SMILES | O=C(C1=CC=C(N(C(N)=O)C2=C(F)C=CC=C2F)N=C1C3=CC=C(F)C=C3F)N |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4734 mL | 12.3671 mL | 24.7341 mL |
| 5 mM | 0.4947 mL | 2.4734 mL | 4.9468 mL |
| 10 mM | 0.2473 mL | 1.2367 mL | 2.4734 mL |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4947 mL |
Description
VX-702 is a highly selective inhibitor of , 14-fold higher potency against the p38α versus p38β.
Features
Highly selective, orally active inhibitor of p38 MAPK.
Targets
| p38α [1] (Cell-free assay) |
| 4 nM-20 nM |
In vitro
Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.